{"id":"NCT01180647","sponsor":"NYU Langone Health","briefTitle":"Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail","officialTitle":"Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2013-07","completion":"2013-07","firstPosted":"2010-08-12","resultsPosted":"2016-04-07","lastUpdate":"2016-04-07"},"enrollment":48,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Opiate Dependence"],"interventions":[{"type":"DRUG","name":"Extended-Release Naltrexone","otherNames":["Vivitrol"]},{"type":"BEHAVIORAL","name":"Motivational Enhancement Counseling","otherNames":[]}],"arms":[{"label":"Extended-release naltrexone (XR-NTX)","type":"ACTIVE_COMPARATOR"},{"label":"Motivational Enhancement Counseling Only","type":"PLACEBO_COMPARATOR"}],"summary":"This pilot study's primary aim is to compare rates of sustained opioid relapse, defined as self-reported opioid use \\>50% (\\>15 of 30) of days during the first 30 days following release from jail, among persons treated with XR-NTX pre-release vs. controls not receiving XR-NTX.","primaryOutcome":{"measure":"Post-Release Opioid Relapse","timeFrame":"Four weeks post-release","effectByArm":[{"arm":"Extended-release Naltrexone (XR-NTX)","deltaMin":6,"sd":null},{"arm":"Motivational Enhancement Counseling Only","deltaMin":15,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["40342086","25703440"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Anticipated XR-NTX Symptoms","Shoulder Seperation","Respiratory Problems"]}}